Testosterone therapy and prostate carcinoma

Current Urology Reports

Volumn 10, Issue 6, 2009, Pages 453-459

  Rhoden, Ernani Luis ^a   Averbeck, Márcio Augusto ^b  

^a UNIVERSIDADE FEDERAL DE CIÊNCIAS DA SAÚDE DE PORTO ALEGRE   (Brazil)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BICALUTAMIDE; ESTROGEN; GONADORELIN AGONIST; GOSERELIN; LEUPRORELIN; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE; TESTOSTERONE CIPIONATE;

ADJUVANT THERAPY; ANDROGEN DEPRIVATION THERAPY; ANDROGEN THERAPY; ANTIGEN DETECTION; BONE METASTASIS; BRACHYTHERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER SCREENING; CANCER SURGERY; CLINICAL TRIAL; DIGITAL RECTAL EXAMINATION; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; EXTERNAL BEAM RADIOTHERAPY; HUMAN; HYPOGONADISM; NONHUMAN; PROSTATE BIOPSY; PROSTATE CARCINOMA; PROSTATECTOMY; REVIEW; TESTOSTERONE BLOOD LEVEL; TUMOR LOCALIZATION;

ANDROGENS; BRACHYTHERAPY; HORMONE REPLACEMENT THERAPY; HUMANS; HYPOGONADISM; MALE; PROSTATECTOMY; PROSTATIC NEOPLASMS; TESTOSTERONE;

EID: 70449495611     PISSN: 15272737     EISSN: 15346285     Source Type: Journal    
DOI: 10.1007/s11934-009-0072-1     Document Type: Review

References (36)

1. E.L. Rhoden M.A. Averbeck P.E. Teloken 2008 Androgen replacement in men undergoing treatment for prostate carcinoma J Sex Med 5 2202 2208 10.1111/j.1743-6109.2008.00925.x 18638000
2. P.K. Agarwal M.G. Oefelein 2005 Testosterone replacement therapy after primary treatment for prostate carcinoma J Urol 173 533 10.1097/01.ju. 0000143942.55896.64 1:CAS:528:DC%2BD2MXitl2qtg%3D%3D 15643240
3. M. Maggi C. Schulman R. Quinton, et al. 2007 The burden of testosterone deficiency syndrome in adult men: economic and quality-of-life impact J Sex Med 44Pt1 1056 1069 10.1111/j.1743-6109.2007.00531.x (Pubitemid 47079639)
4. S. Garos A. Kluck D. Aronoff 2007 Prostate carcinoma patients and their partners: differences in satisfaction indices and psychological variables J Sex Med 4 1394 1403 10.1111/j.1743-6109.2007.00545.x 17634055 (Pubitemid 47337687)
5. C.J. Nelson J.M. Choi J.P. Mulhall A.J. Roth 2007 Determinants of sexual satisfaction in men with prostate carcinoma J Sex Med 4 1422 1427 10.1111/j.1743-6109.2007.00547.x 17634054 (Pubitemid 47337689)
6. C. Huggins C.V. Hodges 1941 Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate Cancer Res 1 293 1:CAS:528: DyaH3MXkvVCrtw%3D%3D
7. P. Stattin S. Lumme L. Tenkanen, et al. 2004 High levels of circulating testosterone are not associated with increased prostate carcinoma risk: a pooled prospective study Int J Cancer 108 418 10.1002/ijc.11572 1:CAS:528: DC%2BD3sXhtVSlsr7J 14648709 (Pubitemid 37549608)
8. S. Wiren T. Stocks S. Rinaldi, et al. 2007 Androgens and prostate carcinoma risk: a prospective study Prostate 67 1230 10.1002/pros.20588 1:CAS:528:DC%2BD2sXhtVWiur7E 17562541 (Pubitemid 47221890)
9. G. Severi H.A. Morris R.J. MacInnis, et al. 2006 Circulating steroid hormones and the risk of prostate carcinoma Cancer Epidemiol Biomarkers Prev 15 86 91 10.1158/1055-9965.EPI-05-0633 1:CAS:528:DC%2BD28XmvVSmtg%3D%3D 16434592
10. L.J. Vatten G. Ursin R.K. Ross, et al. 1997 Androgens in serum and the risk of prostate carcinoma: a nested case-control study from the Janus serum bank in Norway Cancer Epidemiol Biomarkers Prev 6 967 969 1:CAS:528: DyaK2sXnsF2ltLo%3D 9367072
11. C. Chen N.S. Weiss F.Z. Stanczyk, et al. 2003 Endogenous sex hormones and prostate carcinoma risk: a case-control study nested within the Carotene and Retinol Efficacy Trial Cancer Epidemiol Biomarkers Prev 12 1410 1416 1:CAS:528:DC%2BD3sXhtVSqs7zM 14693730
12. A.W. Roddam N.E. Allen P. Appleby, et al. 2008 Endogenous sex hormones and prostate carcinoma: a collaborative analysis of 18 prospective studies J Natl Cancer Inst 100 170 183 10.1093/jnci/djm323 1:CAS:528:DC%2BD1cXivFygsrg%3D 18230794
13. P. Gann C. Hennekens J. Ma, et al. 1996 Prospective study of sex hormone levels and risk of prostate carcinoma J Natl Cancer Inst 88 1118 1126 10.1093/jnci/88.16.1118 1:CAS:528:DyaK28Xlslyhu74%3D 8757191
14. J.K. Parsons H.B. Carter E.A. Platz, et al. 2005 Serum testosterone and the risk of prostate carcinoma: potential implications for testosterone therapy Cancer Epidemiol Biomarkers Prev 14 2257 2260 10.1158/1055-9965.EPI-04-0715 1:CAS:528:DC%2BD2MXhtVWgtbvP 16172240 (Pubitemid 41603276)
15. E.L. Rhoden A. Morgentaler 2004 Risks of testosterone-replacement therapy and recommendations for monitoring N Engl J Med 350 482 10.1056/NEJMra022251 1:CAS:528:DC%2BD2cXos1Wjsw%3D%3D 14749457 (Pubitemid 38133769)
16. J.M. Kaufman R.J. Graydon 2004 Androgen replacement after curative radical prostatectomy for prostate carcinoma in hypogonadal men J Urol 172 920 10.1097/01.ju.0000136269.10161.32 1:CAS:528:DC%2BD2cXms1Grsrg%3D 15310998 (Pubitemid 39096423)
17. S. Bhasin G.R. Cunningham F.J. Hayes, et al. 2006 Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline J Clin Endocrinol Metab 91 1995 10.1210/jc.2005-2847 1:CAS:528:DC%2BD28XlvVChu7g%3D 16720669 (Pubitemid 43854972)
18. W.M. van Weerden G.J. van Steenbrugge A. van Kreuningen, et al. 1991 Assessment of the critical level of androgen for growth response of transplantable human prostatic carcinoma (PC-82) in nude mice J Urol 145 631 1997720
19. O.H. Pearson 1957 Discussion of Dr. Huggins' paper: control of cancers of man by endocrinological methods Cancer Res 17 473 1:CAS:528: DyaG1cXit1SgsQ%3D%3D 13437312
20. J.E. Fowler Jr W.F. Whitmore Jr 1981 The response of metastatic adenocarcinoma of the prostate to exogenous testosterone J Urol 126 372 7277602
21. G.R. Prout Jr W.R. Brewer 1967 Response of men with advanced prostatic carcinoma to exogenous administration of testosterone Cancer 20 1871 10.1002/1097-0142(196711)20:11<1871::AID-CNCR2820201112>3.0.CO;2-D 4168724
22. A. Morgentaler 2006 Testosterone and prostate carcinoma: an historical perspective on a modern myth Eur Urol 50 935 10.1016/j.eururo.2006.06.034 1:CAS:528:DC%2BD28Xht1erur%2FL 16875775 (Pubitemid 44486489)
23. L.S. Marks N.A. Mazer E. Mostaghel, et al. 2006 Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial JAMA 296 2351 10.1001/jama.296.19.2351 1:CAS:528:DC%2BD28Xht1ansb%2FM 17105798 (Pubitemid 44749363)
24. A.I. El-Sakka H.M. Hassoba A.M. Elbakry H.A. Hassan 2005 Prostatic specific antigen in patients with hypogonadism: effect of testosterone replacement J Sex Med 2 235 240 10.1111/j.1743-6109.2005.20233.x 1:CAS:528:DC%2BD2MXjtlalurc%3D 16422891 (Pubitemid 40468179)
25. S. Bhasin L. Woodhouse R. Casaburi, et al. 2001 Testosterone dose-response relationships in healthy young men Am J Physiol Endocrinol Metab 281 E1172 1:CAS:528:DC%2BD3MXptlKmsbc%3D 11701431
26. C.S. Cooper P.J. Perry A.E. Sparks, et al. 1998 Effect of exogenous testosterone on prostate volume, serum and semen prostate specific antigen levels in healthy young men J Urol 159 441 10.1016/S0022-5347(01)63944-2 1:CAS:528:DyaK1cXmsFOhs74%3D 9649259 (Pubitemid 28049252)
27. K.R. Loughlin J.P. Richie 1997 Prostate carcinoma after exogenous testosterone treatment for impotence J Urol 157 1845 10.1016/S0022-5347(01) 64881-X 1:STN:280:DyaK2s3ms1yhsg%3D%3D 9112543 (Pubitemid 27171790)
28. M.J. Curran W. Bihrle 3rd 1999 Dramatic rise in prostate-specific antigen after androgen replacement in a hypogonadal man with occult adenocarcinoma of the prostate Urology 53 423 10.1016/S0090-4295(98)00348-3 1:STN:280: DyaK1M7ivFymsw%3D%3D 9933071 (Pubitemid 29063343)
29. G.J. Bubley 2001 Is the flare phenomenon clinically significant? Urology 58 5 10.1016/S0090-4295(01)01235-3 1:STN:280:DC%2BD3Mvlslegsw%3D%3D 11502435 (Pubitemid 32743396)
30. J.M. Kuhn T. Billebaud H. Navratil, et al. 1989 Prevention of the transient adverse effects of a gonadotropin-releasing hormone analogue (buserelin) in metastatic prostatic carcinoma by administration of an antiandrogen (nilutamide) N Engl J Med 321 413 1:STN:280:DyaL1MzksVWgtg%3D%3D 2503723
31. K. Tomera D. Gleason M. Gittelman, et al. 2001 The gonadotropin-releasing hormone antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: initial results of endocrinological and biochemical efficacies in patients with prostate carcinoma J Urol 165 1585 10.1016/S0022-5347(05)66353-7 1:CAS:528:DC%2BD3MXjvVaitbs%3D 11342922
32. M. Khera E.D. Grober B. Najari, et al. 2009 Testosterone replacement therapy following radical prostatectomy J Sex Med 4 1165 1170 10.1111/j.1743-6109.2009.01161.x
33. M.F. Sarosdy 2007 Testosterone replacement for hypogonadism after treatment of early prostate carcinoma with brachytherapy Cancer 109 536 10.1002/cncr.22438 1:CAS:528:DC%2BD2sXitV2itrk%3D 17183557 (Pubitemid 46190961)
34. Morales A, Black AM, Emerson LE: Testosterone administration to men with testosterone deficiency syndrome after external beam radiotherapy for localized prostate carcinoma: preliminary observations. BJU Int 2008, doi:10.1111/j.1464- 410X.2008.07882.x.
35. A. Morgentaler C.O. Bruning 3rd W.C. DeWolf 1996 Occult prostate carcinoma in men with low serum testosterone levels JAMA 276 1904 10.1001/jama.276.23.1904 1:STN:280:DyaK2s7it1eqtQ%3D%3D 8968017 (Pubitemid 26419188)
36. R. Shabsigh E.D. Crawford A. Nehra K.M. Slawin 2009 Testosterone therapy in hypogonadal men and potential prostate cancer risk: a systematic review Int J Impot Res 21 9 23 10.1038/ijir.2008.31 1:CAS:528:DC%2BD1MXktl2lug%3D%3D 18633357